Objective: To measure the serum levels of Fetuin-A, ischemia-modified albumin (IMA), and ferritin in hospitalized patients with severe COVID-19in Baghdad, Iraq. Moreover, to determine these biomarkers' cut-off valuesthat differentiate between severely ill patients and control subjects. Methods: This case-control study was done from 15 September to the end of December 2021 and involved a review of the files and collectionof blood samples from patients (n=45, group1) hospitalized in COVID-19 treatment centersbecause of severe symptoms compared tohealthy subjects as controls (n=44, group2). Results: Fetuin-A serum levels were not statistically different between patients and controls. In contrast, IMA and ferritin levels were significantly different between the 2 groups, with patients' levelsbeing greater than control participants' (p 0.05). The critical values for the Fetuin-A, IMA, and ferritin tests were 393.78 mg/L, 59.22 ng/ml, and 126 µg/L, respectively, with concentration curves of 0.58, 0.70, and 0.93 for each. Conclusions: Patients and controls showed no significant difference in Fetuin-A levels in the blood. However, IMA and ferritin levels werehigher in people suffering from acute COVID-19 infection than in controls, with Fetuin-A values less than 393.78 mg/L andIMA and ferritin valueshigher than 59.22 ng/mland 126,000 μg/L, respectively.
